FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation

Pharmaceutical Investing

Cerecor (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs). As quoted in …

Cerecor (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs).

As quoted in the press release:

The FDA granted ODD to:  CERC-801, D-galactose for the treatment of Phosphoglucomutase 1 (PGM1) Deficiency; CERC-802, D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency; and CERC-803, L-fucose for the treatment of Congenital Disorder of Glycosylation IIc (CDG-IIc).

Each indication is an ultra-rare CDG estimated to have fewer than 1,000 patients in the United States. All three programs have previously been granted Rare Pediatric Disease Designation (RPDD) by the FDA. Cerecor completed pre-IND meetings with the FDA and seeks to leverage the 505(b)(2) pathway to expedite approval of each product.

Peter Greenleaf, Cerecor’s CEO, stated, “We are proud and excited to be a leader in CDG drug development.  We’ve advanced the development of each program on multiple fronts and we look forward to continued progress in our collaborations with researchers, physicians and, most importantly, patients. Our goal is to put these therapies in the hands of patients and their caregivers, and we hope the 505(b)(2) pathway continues to provide flexibility and acceleration of these efforts.”

Click here to read the full press release.

The Conversation (0)
×